Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,650 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07317193Recruiting
Genetic causes of adult bile duct disease
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
Milan, MilanoAges 18–65 - NCT05667194RecruitingPhase 1
Early study of KH617 for advanced brain and solid tumors
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06911489RecruitingPhase 1
Safety trial of a new targeted therapy for advanced solid tumors
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
ShanghaiAges 18–80 - NCT06895603Recruiting
New cuff to measure blood flow during heart procedures
This trial tests a new upper-arm cuff that may measure your heart's blood flow without needing an extra tube in your heart. If you already need a special heart catheter and a wrist arterial line, this study will see if the cuff works just as well.
Charlottesville, VirginiaAges 18 years+ - NCT07680803RecruitingPhase 2
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
Rome, LazioAges 3–35 - NCT05876715RecruitingPhase 1/Phase 2
Testing 3 immunotherapy drugs for hard-to-remove soft tissue cancer
This Phase 1/2 study tests lurbinectedin plus two immune checkpoint medicines (ipilimumab and nivolumab) for soft tissue sarcoma that is hard to remove or has spread. It aims to see how well the combination works and how safe it is, especially for people with limited treatment options.
Santa Monica, CaliforniaAges 18–90 - NCT05689853RecruitingPhase 1/Phase 2
Testing two targeted cancer drugs for advanced solid tumors
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
Beijing, Beijing MunicipalityAges 18–75 - NCT06818747Recruiting
Comparing two cornea transplant methods for advanced bullous keratopathy
This trial compares two types of cornea transplant surgery (PKP and DSAEK) to see which one helps people with severe corneal swelling see better after two years. It may be an option if you have advanced bullous keratopathy and need a first-time cornea transplant.
BesançonAges 50 years+ - NCT03080974RecruitingPhase 2
Study tests immunotherapy plus electroporation for advanced pancreatic cancer
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Louisville, KentuckyAges 18 years+ - NCT07373691Enrolling by invitation
Scoring system study for advanced pancreatic cancer
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
ShanghaiAges 18 years+ - NCT05831033RecruitingEarly Phase 1
Your own immune T-cells to treat advanced solid tumors
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06824155RecruitingEarly Phase 1
Radioactive drug for HER2-positive advanced cancers
This trial tests a radioactive drug (lutetium-177) that targets the HER2 protein, which is found on some cancer cells. It's for people with advanced, HER2-positive or HER2-low solid tumors that haven't responded to other treatments.
Kingswood, New South WalesAges 18 years+ - NCT06737731RecruitingPhase 1/Phase 2
SHR-1681 for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06732609Recruiting
Skin study using advanced imaging
This trial uses a special camera to study the skin around the mouth in healthy young adults. It aims to understand normal skin features.
RomaAges 20–35 - NCT06728670Recruiting
Tranexamic acid in ovarian cancer surgery
This study looks at how the drug tranexamic acid (TXA) works in the body during and after surgery for advanced ovarian cancer. It aims to find the best dose to help control bleeding without increasing the risk of blood clots.
Hangzhou, ZhejiangAges 20–64 - NCT07298772RecruitingPhase 1/Phase 2
Testing SHR-4375 with other therapies for solid tumors
This study tests a new drug called SHR-4375 combined with other cancer treatments for people with advanced solid tumors that haven't gotten better with standard care. The goal is to see if the combination is safe and works against the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06695689RecruitingEarly Phase 1
LM303 injection for advanced solid tumors
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
TianjinAges 18 years+ - NCT07652125Recruiting
RGL-270 vaccine plus immunotherapy for advanced lung cancer
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
Guangzhou, Other (Non U.s.)Ages 18 years+ - NCT07377045RecruitingPhase 1
New combo for advanced pancreatic cancer
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT07446153RecruitingPhase 1/Phase 2
HRS-8364 for advanced solid tumors
This trial tests a new medicine, HRS-8364, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–75 - NCT06603844RecruitingPhase 1/Phase 2
Study of CRB-601-01 for advanced solid tumors
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06597539Recruiting
PET scan to monitor immunotherapy in advanced liver cancer
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07501351RecruitingPhase 2
Comparing two therapies for advanced liver cancer after first treatment fails
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,650 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.